Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.

Pharmaceutical research - 1 Jun 2016

Gale Andrew J, Bhat Vikas, Pellequer Jean-Luc, Griffin John H, Mosnier Laurent O, Von Drygalski Annette

Abstract excerpt

PURPOSE: Activated (super)Factor V ((super)FVa) is a novel engineered FV with excellent prohemostatic efficacy. (Super)FVa has three APC cleavage site mutations and an interdomain disulfide bond. Stability, pharmacokinetics, and immunogenic and thrombogenic potential are reported here. METHODS: Stability and circulating half-life were determined after incubation in buffer and human plasma, and after injection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Stability
Share to Factor VIII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrin

Share to Half-Life

Share to Hemophilia A

Share to Hemostatics

Share to Injections, Intravenous

Share to Thrombin

Source

Open in PubMed Open full text

Identifiers

PMID: 26960296
DOI: 10.1007/s11095-016-1895-3
PMCID: PMC4854778

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.PMID 26960296Read ↗

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapySemantic proximity Read ↗

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Semantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.Semantic proximity Read ↗

Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.Semantic proximity Read ↗

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.Semantic proximity Read ↗

Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.Semantic proximity Read ↗

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.Semantic proximity Read ↗

Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.Semantic proximity Read ↗

The Function of extravascular coagulation factor IX in haemostasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.